Coave Therapeutics is a clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases. 
We are pushing the boundaries of gene therapy through application of our AAV-Ligand Conjugates platform (ALIGATER) that enables targeted delivery, enhanced gene transduction and tissue distribution to improve the effectiveness of advanced gene therapies for rare diseases.
Our strategy is to advance a pipeline of novel therapies targeting rare ocular and CNS diseases where targeted gene therapy has the potential to be most effective, where there is a clear unmet need and where success will provide rapid validation of our ALIGATER platform.



Biotechnology

Coave Therapeutics

Rodolphe Clerval

Julien Berger

Patricia Françon

Catherine Mathis

The Research and Development team at Coave Therapeutics is dedicated to advancing innovative gene therapies for rare ocular and CNS diseases. Their focus includes designing and optimizing drug candidates using the AAV-Ligand Conjugates platform (ALIGATER) to ensure targeted delivery and enhanced therapeutic effects. The team conducts preclinical studies, oversees translational science efforts, and collaborates with experts to push the boundaries of gene therapy, ultimately aiming to address unmet medical needs in these challenging conditions.

Research and Development

About

Team members

Other teams at Coave Therapeutics

Leadership Team